PRESS RELEASES

All Releases
Aug 17, 2018

AUSTIN, Texas , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced the closing of its previously announced registered direct offering of 8,860,778 shares of its common stock, which was priced at-the-market at a purchase price of

Aug 16, 2018

– Proceeds to Be Used for Drug Development, General Corporate Purpose – AUSTIN, Texas , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional investors for the

Aug 15, 2018
– NIH Grant will Support Clinical Testing of PTI-125 – – Initiation of Phase II Study Expected Q4 2018 – AUSTIN, Texas , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded
Aug 06, 2018

- Corporate Reorganization Expected Shortly - AUSTIN, Texas , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) for its New Drug Application (NDA) for REMOXY,

Jul 26, 2018
AUSTIN, Texas , July 26, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today reported financial results for the second quarter ended June 30 , 2018.  Net loss was $2.5 million , or $0.36 per share.  This compared to a net loss of $4.2 million , or $0.64
Jun 26, 2018
AUSTIN, Texas , June 26, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
May 09, 2018
– June 26 th Advisory Committee Meeting for REMOXY ER –  – August 7 th PDUFA Target Date for REMOXY ER – AUSTIN, Texas , May 09, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today reported financial results for the first quarter ended March 31 , 2018. 
Mar 19, 2018
AUSTIN, Texas , March 19, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, announced today that the U.S. Food and Drug Administration ( FDA ) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended-release
Mar 01, 2018
AUSTIN, Texas , March 01, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration ( FDA ) has determined that a New Drug Application (NDA) for REMOXY ER, the Company’s lead drug candidate, is sufficiently complete to permit a
Feb 13, 2018
AUSTIN, Texas , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the resubmission to the U.S. Food and Drug Administration ( FDA ) of a New Drug Application (NDA) for REMOXY ® ER, its lead drug candidate.  The Company expects a six-month review cycle by FDA .